Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS)

    Summary
    EudraCT number
    2017-004394-14
    Trial protocol
    NL   FR   GB   DE   BE   DK   PL   IT  
    Global end of trial date
    26 Jul 2022

    Results information
    Results version number
    v1(current)
    This version publication date
    12 Jun 2024
    First version publication date
    12 Jun 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ZP1848-17111
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    IND: 133151
    Sponsors
    Sponsor organisation name
    Zealand Pharma A/S
    Sponsor organisation address
    Sydmarken 11, Søborg, Denmark, DK-2860
    Public contact
    Head of clinical operations, Zealand Pharma A/S, +45 8877 3600, info@zealandpharma.com
    Scientific contact
    Head of clinical operations, Zealand Pharma A/S, +45 8877 3600, info@zealandpharma.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Sep 2022
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    26 Jul 2022
    Global end of trial reached?
    Yes
    Global end of trial date
    26 Jul 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To confirm the efficacy of glepaglutide in reducing parenteral support (PS) volume in Short Bowel Syndrome (SBS) patients.
    Protection of trial subjects
    This trial was conducted in accordance with the ethical principles of Good Clinical Practice (GCP) and the Declaration of Helsinki, as well as in accordance with other applicable local ethical and legal requirements. The investigator had both ethical and legal responsibility to ensure that each individual being considered for inclusion in this trial was given a full explanation of the protocol. Informed consent was obtained and documented prior to initiation of any procedures.
    Background therapy
    Of the 106 patients randomized, 104 used one or more concomitant medications at the beginning of the treatment period, the most commonly used concomitant medications commenced or ongoing at the first dose date belonged to the ATC class ‘Alimentary tract and metabolism’.
    Evidence for comparator
    Placebo
    Actual start date of recruitment
    04 Oct 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 23
    Country: Number of subjects enrolled
    Canada: 4
    Country: Number of subjects enrolled
    Netherlands: 4
    Country: Number of subjects enrolled
    Poland: 27
    Country: Number of subjects enrolled
    United Kingdom: 9
    Country: Number of subjects enrolled
    Belgium: 10
    Country: Number of subjects enrolled
    Denmark: 8
    Country: Number of subjects enrolled
    France: 9
    Country: Number of subjects enrolled
    Germany: 12
    Worldwide total number of subjects
    106
    EEA total number of subjects
    70
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    81
    From 65 to 84 years
    25
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    This trial was conducted in (number of sites that randomized patients in parenthesis) Belgium (1), Denmark (2), France (2), Germany (5), the Netherlands (1), Poland (3), Canada (3), the US (7), and the UK (5).

    Pre-assignment
    Screening details
    After Screening period, patients enter a PS Optimization and Stabilization Phase before randomization. During Optimization Phase, the Investigator may change PS volume and content if the patient is unstable or not optimized. During Stabilization Phase the patient need to fulfill pre-specified stability criteria before the patient can be randomized.

    Period 1
    Period 1 title
    Treatment period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst, Carer, Assessor
    Blinding implementation details
    Both the patient and investigator were blinded to the actual content of each vial (active or placebo). Patients were randomly assigned to trial treatments using an automatic, Interactive Response Technology (IRT).

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Glepaglutide 10 mg twice weekly
    Arm description
    Patients randomized to receive twice weekly a subcutaneous injection of 10 mg Glepaglutide in patients' preferred injection site area: abdomen or thigh.
    Arm type
    Experimental

    Investigational medicinal product name
    Glepaglutide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Glepaglutide 10 mg was administered twice weekly as a subcutaneous injection in patients' preferred injection site area: abdomen or thigh.

    Arm title
    Glepaglutide 10 mg once weekly
    Arm description
    Patients randomized to receive once weekly a subcutaneous injection of 10 mg Glepaglutide and once weekly an injection with placebo in patients' preferred injection site area: abdomen or thigh.
    Arm type
    Experimental

    Investigational medicinal product name
    Glepaglutide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Glepaglutide 10 mg was administered once weekly as a subcutaneous injection in patients' preferred injection site area: abdomen or thigh.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Placebo was administered once weekly as a subcutaneous injection in patients' preferred injection site area: abdomen or thigh.

    Arm title
    Placebo
    Arm description
    Patients randomized to receive twice weekly a subcutaneous injection of placebo in patients' preferred injection site area: abdomen or thigh.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Placebo was administered twice weekly as a subcutaneous injection in patients' preferred injection site area: abdomen or thigh.

    Number of subjects in period 1
    Glepaglutide 10 mg twice weekly Glepaglutide 10 mg once weekly Placebo
    Started
    35
    35
    36
    Completed
    31
    35
    36
    Not completed
    4
    0
    0
         Consent withdrawn by subject
    2
    -
    -
         Adverse event, non-fatal
    2
    -
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Glepaglutide 10 mg twice weekly
    Reporting group description
    Patients randomized to receive twice weekly a subcutaneous injection of 10 mg Glepaglutide in patients' preferred injection site area: abdomen or thigh.

    Reporting group title
    Glepaglutide 10 mg once weekly
    Reporting group description
    Patients randomized to receive once weekly a subcutaneous injection of 10 mg Glepaglutide and once weekly an injection with placebo in patients' preferred injection site area: abdomen or thigh.

    Reporting group title
    Placebo
    Reporting group description
    Patients randomized to receive twice weekly a subcutaneous injection of placebo in patients' preferred injection site area: abdomen or thigh.

    Reporting group values
    Glepaglutide 10 mg twice weekly Glepaglutide 10 mg once weekly Placebo Total
    Number of subjects
    35 35 36 106
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    23 28 30 81
        From 65-84 years
    12 7 6 25
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    56.9 ( 13.4 ) 54.0 ( 12.0 ) 55.0 ( 11.8 ) -
    Gender categorical
    Units: Subjects
        Female
    19 18 30 67
        Male
    16 17 6 39

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Glepaglutide 10 mg twice weekly
    Reporting group description
    Patients randomized to receive twice weekly a subcutaneous injection of 10 mg Glepaglutide in patients' preferred injection site area: abdomen or thigh.

    Reporting group title
    Glepaglutide 10 mg once weekly
    Reporting group description
    Patients randomized to receive once weekly a subcutaneous injection of 10 mg Glepaglutide and once weekly an injection with placebo in patients' preferred injection site area: abdomen or thigh.

    Reporting group title
    Placebo
    Reporting group description
    Patients randomized to receive twice weekly a subcutaneous injection of placebo in patients' preferred injection site area: abdomen or thigh.

    Primary: Change in actual weekly PS volume from baseline to Week 24

    Close Top of page
    End point title
    Change in actual weekly PS volume from baseline to Week 24
    End point description
    End point type
    Primary
    End point timeframe
    From baseline to Week 24
    End point values
    Glepaglutide 10 mg twice weekly Glepaglutide 10 mg once weekly Placebo
    Number of subjects analysed
    35
    35
    36
    Units: number
    least squares mean (confidence interval 95%)
        Week 24
    -5.13 (-6.24 to -4.02)
    -3.76 (-4.96 to -2.56)
    -2.85 (-3.93 to -1.77)
    Statistical analysis title
    Primary analysis - MI CR
    Statistical analysis description
    The primary analysis uses a restricted maximum likelihood (REML)–based repeated-measures approach to compare treatment groups with respect to the mean change from baseline in actual weekly PS volume at Week 24. The primary comparisons are the contrasts (differences in least squares means) between the glepaglutide treatment groups and the placebo group at the Week 24 visit in this mixed-effects model for repeated measures.
    Comparison groups
    Glepaglutide 10 mg twice weekly v Placebo
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0039
    Method
    Mixed models analysis
    Parameter type
    Difference to Placebo
    Point estimate
    -2.28
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -3.83
         upper limit
    -0.73
    Statistical analysis title
    Primary analysis - MI CR
    Statistical analysis description
    The primary analysis uses a restricted maximum likelihood (REML)–based repeated-measures approach to compare treatment groups with respect to the mean change from baseline in actual weekly PS volume at Week 24. The primary comparisons are the contrasts (differences in least squares means) between the glepaglutide treatment groups and the placebo group at the Week 24 visit in this mixed-effects model for repeated measures.
    Comparison groups
    Glepaglutide 10 mg once weekly v Placebo
    Number of subjects included in analysis
    71
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.27
    Method
    Mixed models analysis
    Parameter type
    Difference to Placebo
    Point estimate
    -0.91
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -2.52
         upper limit
    0.71

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All AEs, whether serious or non-serious, were to be reported from the time a signed and dated Informed Consent Form (ICF) was obtained until the end of the post-treatment follow-up period.
    Adverse event reporting additional description
    For 'Stoma complications' and related preferred terms, the denominators used in the calculation of % are based on patients with a small intestine stoma (Glepa 10 mg TW: N=17; Glepa 10 mg OW: N=20; Placebo: N=21).
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    24.1
    Reporting groups
    Reporting group title
    Glepaglutide 10 mg twice weekly
    Reporting group description
    Patients randomized to receive twice weekly a subcutaneous injection of 10 mg Glepaglutide.

    Reporting group title
    Glepaglutide 10 mg once weekly
    Reporting group description
    Patients randomized to receive once weekly a subcutaneous injection of 10 mg Glepaglutide and once weekly a subcutaneous injection with placebo.

    Reporting group title
    Placebo
    Reporting group description
    Patients randomized to receive twice weekly a subcutaneous injection of placebo.

    Serious adverse events
    Glepaglutide 10 mg twice weekly Glepaglutide 10 mg once weekly Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    9 / 35 (25.71%)
    9 / 35 (25.71%)
    7 / 36 (19.44%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    Injury, poisoning and procedural complications
    Stoma site haemorrhage
         subjects affected / exposed [1]
    1 / 17 (5.88%)
    0 / 20 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Acetabulum fracture
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Alcohol poisoning
         subjects affected / exposed
    0 / 35 (0.00%)
    0 / 35 (0.00%)
    1 / 36 (2.78%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Procedural pneumothorax
         subjects affected / exposed
    0 / 35 (0.00%)
    0 / 35 (0.00%)
    1 / 36 (2.78%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Peripheral arterial occlusive disease
         subjects affected / exposed
    0 / 35 (0.00%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Blood loss anaemia
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Iron deficiency anaemia
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 35 (2.86%)
    2 / 35 (5.71%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Catheter site necrosis
         subjects affected / exposed
    0 / 35 (0.00%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Haemorrhoids
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    0 / 35 (0.00%)
    0 / 35 (0.00%)
    1 / 36 (2.78%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    0 / 35 (0.00%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Device related sepsis
         subjects affected / exposed
    2 / 35 (5.71%)
    2 / 35 (5.71%)
    1 / 36 (2.78%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Large intestine infection
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vascular device infection
         subjects affected / exposed
    0 / 35 (0.00%)
    2 / 35 (5.71%)
    2 / 36 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    0 / 35 (0.00%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal viral infection
         subjects affected / exposed
    0 / 35 (0.00%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Product issues
    Device breakage
         subjects affected / exposed
    0 / 35 (0.00%)
    0 / 35 (0.00%)
    1 / 36 (2.78%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Device malfunction
         subjects affected / exposed
    0 / 35 (0.00%)
    0 / 35 (0.00%)
    1 / 36 (2.78%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Metabolic acidosis
         subjects affected / exposed
    1 / 35 (2.86%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Notes
    [1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
    Justification: For the 'Stoma complications' and related preferred terms, the denominators used in the calculation of % are based on patients with small intestine stoma (Glepa 10 mg TW: N=17; Glepa 10 mg OW: N=20; Placebo: N=21).
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Glepaglutide 10 mg twice weekly Glepaglutide 10 mg once weekly Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    30 / 35 (85.71%)
    31 / 35 (88.57%)
    24 / 36 (66.67%)
    Investigations
    Weight decreased
         subjects affected / exposed
    2 / 35 (5.71%)
    1 / 35 (2.86%)
    2 / 36 (5.56%)
         occurrences all number
    2
    1
    2
    Aspartate aminotransferase increased
         subjects affected / exposed
    2 / 35 (5.71%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences all number
    2
    1
    0
    Injury, poisoning and procedural complications
    Stoma site oedema
         subjects affected / exposed [2]
    4 / 17 (23.53%)
    2 / 20 (10.00%)
    0 / 21 (0.00%)
         occurrences all number
    4
    11
    0
    Stoma complication
         subjects affected / exposed [3]
    1 / 17 (5.88%)
    2 / 20 (10.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    2
    0
    Stomal hernia
         subjects affected / exposed [4]
    1 / 17 (5.88%)
    0 / 20 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    0
    0
    Procedural pain
         subjects affected / exposed
    2 / 35 (5.71%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences all number
    3
    2
    0
    Fall
         subjects affected / exposed
    0 / 35 (0.00%)
    2 / 35 (5.71%)
    0 / 36 (0.00%)
         occurrences all number
    0
    2
    0
    Stoma site irritation
         subjects affected / exposed [5]
    0 / 17 (0.00%)
    1 / 20 (5.00%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    4 / 35 (11.43%)
    2 / 35 (5.71%)
    3 / 36 (8.33%)
         occurrences all number
    5
    2
    7
    Dizziness
         subjects affected / exposed
    2 / 35 (5.71%)
    2 / 35 (5.71%)
    0 / 36 (0.00%)
         occurrences all number
    3
    2
    0
    General disorders and administration site conditions
    Injection site reaction
         subjects affected / exposed
    9 / 35 (25.71%)
    15 / 35 (42.86%)
    0 / 36 (0.00%)
         occurrences all number
    135
    114
    0
    Injection site erythema
         subjects affected / exposed
    5 / 35 (14.29%)
    6 / 35 (17.14%)
    1 / 36 (2.78%)
         occurrences all number
    6
    60
    1
    Pyrexia
         subjects affected / exposed
    4 / 35 (11.43%)
    1 / 35 (2.86%)
    1 / 36 (2.78%)
         occurrences all number
    4
    1
    2
    Fatigue
         subjects affected / exposed
    4 / 35 (11.43%)
    4 / 35 (11.43%)
    0 / 36 (0.00%)
         occurrences all number
    4
    6
    0
    Injection site pain
         subjects affected / exposed
    4 / 35 (11.43%)
    3 / 35 (8.57%)
    0 / 36 (0.00%)
         occurrences all number
    31
    29
    0
    Injection site induration
         subjects affected / exposed
    4 / 35 (11.43%)
    2 / 35 (5.71%)
    0 / 36 (0.00%)
         occurrences all number
    44
    3
    0
    Oedema peripheral
         subjects affected / exposed
    4 / 35 (11.43%)
    0 / 35 (0.00%)
    2 / 36 (5.56%)
         occurrences all number
    4
    0
    2
    Injection site irritation
         subjects affected / exposed
    3 / 35 (8.57%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences all number
    13
    0
    0
    Feeling hot
         subjects affected / exposed
    2 / 35 (5.71%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences all number
    4
    0
    0
    Injection site rash
         subjects affected / exposed
    2 / 35 (5.71%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences all number
    2
    0
    0
    Malaise
         subjects affected / exposed
    2 / 35 (5.71%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences all number
    2
    0
    0
    Injection site pruritus
         subjects affected / exposed
    1 / 35 (2.86%)
    4 / 35 (11.43%)
    1 / 36 (2.78%)
         occurrences all number
    3
    22
    1
    Complication associated with device
         subjects affected / exposed
    0 / 35 (0.00%)
    2 / 35 (5.71%)
    0 / 36 (0.00%)
         occurrences all number
    0
    2
    0
    Blood and lymphatic system disorders
    Iron deficiency anaemia
         subjects affected / exposed
    2 / 35 (5.71%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences all number
    2
    0
    0
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    7 / 35 (20.00%)
    3 / 35 (8.57%)
    1 / 36 (2.78%)
         occurrences all number
    8
    3
    8
    Abdominal pain
         subjects affected / exposed
    5 / 35 (14.29%)
    6 / 35 (17.14%)
    2 / 36 (5.56%)
         occurrences all number
    8
    7
    2
    Vomiting
         subjects affected / exposed
    3 / 35 (8.57%)
    6 / 35 (17.14%)
    0 / 36 (0.00%)
         occurrences all number
    5
    6
    0
    Abdominal discomfort
         subjects affected / exposed
    2 / 35 (5.71%)
    0 / 35 (0.00%)
    2 / 36 (5.56%)
         occurrences all number
    2
    0
    3
    Dry mouth
         subjects affected / exposed
    2 / 35 (5.71%)
    0 / 35 (0.00%)
    0 / 36 (0.00%)
         occurrences all number
    2
    0
    0
    Diarrhoea
         subjects affected / exposed
    1 / 35 (2.86%)
    2 / 35 (5.71%)
    1 / 36 (2.78%)
         occurrences all number
    1
    2
    1
    Abdominal distension
         subjects affected / exposed
    1 / 35 (2.86%)
    2 / 35 (5.71%)
    0 / 36 (0.00%)
         occurrences all number
    1
    2
    0
    Abdominal pain lower
         subjects affected / exposed
    0 / 35 (0.00%)
    2 / 35 (5.71%)
    0 / 36 (0.00%)
         occurrences all number
    0
    2
    0
    Respiratory, thoracic and mediastinal disorders
    Oropharyngeal pain
         subjects affected / exposed
    2 / 35 (5.71%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences all number
    2
    1
    0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    1 / 35 (2.86%)
    2 / 35 (5.71%)
    1 / 36 (2.78%)
         occurrences all number
    1
    3
    1
    Musculoskeletal and connective tissue disorders
    Muscle spasms
         subjects affected / exposed
    2 / 35 (5.71%)
    1 / 35 (2.86%)
    3 / 36 (8.33%)
         occurrences all number
    2
    1
    3
    Back pain
         subjects affected / exposed
    2 / 35 (5.71%)
    1 / 35 (2.86%)
    1 / 36 (2.78%)
         occurrences all number
    2
    1
    1
    Osteoporosis
         subjects affected / exposed
    0 / 35 (0.00%)
    2 / 35 (5.71%)
    0 / 36 (0.00%)
         occurrences all number
    0
    2
    0
    Arthralgia
         subjects affected / exposed
    1 / 35 (2.86%)
    1 / 35 (2.86%)
    3 / 36 (8.33%)
         occurrences all number
    1
    1
    4
    Infections and infestations
    Urinary tract infection
         subjects affected / exposed
    2 / 35 (5.71%)
    0 / 35 (0.00%)
    2 / 36 (5.56%)
         occurrences all number
    2
    0
    2
    Nasopharyngitis
         subjects affected / exposed
    1 / 35 (2.86%)
    1 / 35 (2.86%)
    3 / 36 (8.33%)
         occurrences all number
    1
    1
    4
    Gastrointestinal bacterial overgrowth
         subjects affected / exposed
    0 / 35 (0.00%)
    3 / 35 (8.57%)
    0 / 36 (0.00%)
         occurrences all number
    0
    3
    0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    4 / 35 (11.43%)
    1 / 35 (2.86%)
    0 / 36 (0.00%)
         occurrences all number
    4
    1
    0
    Hypomagnesaemia
         subjects affected / exposed
    0 / 35 (0.00%)
    2 / 35 (5.71%)
    1 / 36 (2.78%)
         occurrences all number
    0
    2
    1
    Hyperuricaemia
         subjects affected / exposed
    0 / 35 (0.00%)
    0 / 35 (0.00%)
    2 / 36 (5.56%)
         occurrences all number
    0
    0
    2
    Notes
    [2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: For the 'Stoma complications' and related preferred terms, the denominators used in the calculation of % are based on patients with small intestine stoma (Glepa 10 mg TW: N=17; Glepa 10 mg OW: N=20; Placebo: N=21).
    [3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: For the 'Stoma complications' and related preferred terms, the denominators used in the calculation of % are based on patients with small intestine stoma (Glepa 10 mg TW: N=17; Glepa 10 mg OW: N=20; Placebo: N=21).
    [4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: For the 'Stoma complications' and related preferred terms, the denominators used in the calculation of % are based on patients with small intestine stoma (Glepa 10 mg TW: N=17; Glepa 10 mg OW: N=20; Placebo: N=21).
    [5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
    Justification: For the 'Stoma complications' and related preferred terms, the denominators used in the calculation of % are based on patients with small intestine stoma (Glepa 10 mg TW: N=17; Glepa 10 mg OW: N=20; Placebo: N=21).

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    24 Oct 2018
    Protocol v. 4.0 • Reduction in weekly PS volume from baseline to Week 24 was changed from a key secondary endpoint to a primary endpoint • Clinical response, defined as achieving at least 20% reduction in PS volume from baseline to both Weeks 20 and 24 was changed from the primary endpoint to a key secondary endpoint • Reduction of at least 20% in PS volume from baseline to both Weeks 12 and 24 was changed from key secondary endpoint to secondary efficacy endpoint. • Changed the definition of the intention-to-treat (ITT) analysis set to include those we received at least 1 dose of investigational product • Added that patients were to measure their body weight weekly • Added the estimand section • Added that all efforts should be made to complete the assessment of actual PS volume at Week 24 in patients who could not adhere to the visit schedule • Added that a maximum of 4 week of treatment pause was allowed. After that, the patient was to be discontinued for the remainder of the trial but encouraged to attend all visits and complete all assessments. • Added lab sampling in case of suspected liver injury to unscheduled visit • Adapted the SBS characteristics and disease history based on a new reference • Added that all relevant previous treatments, including treatment with teduglutide, any other GLP-2 analogs or native GLP-2 was to be recorded in the eCRF • Added pancreatitis and cholecystitis to the list of AESIs
    18 Sep 2019
    Protocol v. 5.0 Extended the screening period from 1 week to 2 weeks • Added that a second optimization phase may be done • Added reduction in duration of PS infusions per week from baseline to other efficacy endpoints • Added FSH testing to confirm menopause • Added the Exit Interview at UK and US sites only • Added reduction in duration of PS infusions per week from baseline as another efficacy endpoint and described how the results are presented • Added that for each AESI, a time to event analysis was performed
    12 Nov 2019
    Protocol v. 6.0 Clarification on AE reporting in cases of worsening of severity or seriousness
    05 Dec 2019
    Protocol v. 7.0 • Added change in weight from baseline to Week 24 as a secondary efficacy endpoint and described how the results are presented • Updated the trial design figure • Stated that the randomization codes will be supplied to the bioanalytical teams at Charles River (PK analyses) and Syrinx (ADA analyses).
    15 Oct 2020
    Protocol v. 8.0 • Added wording about blinding/unblinding of samples and that all PK and ADA samples are shipped to the laboratory.
    03 Mar 2021
    Protocol v. 9.0 • Added that exit interviews will be conducted at Danish, French and German sites as well as the UK and US sites • Add a longer enrollment period due to COVID-19 • Changed the trial design to a group sequential design incorporating one interim analysis for efficacy/futility
    27 Jan 2022
    Protocol v. 10.0 • Removed the planned interim analysis in order to stop the trial with a reduced sample size • Updated the number to patients expected • Updated the power calculation based on the reduced patient population

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:07:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA